| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/LIV.12191 |
| P698 | PubMed publication ID | 23672463 |
| P50 | author | Ian Young | Q43287105 |
| Stephen O'Neill | Q53281195 | ||
| P2093 | author name string | David R McCance | |
| Mark E O'Donnell | |||
| Jane McEneny | |||
| Neil I McDougall | |||
| Michael E Callender | |||
| William J Cash | |||
| P2860 | cites work | The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials | Q24646234 |
| Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials | Q33857895 | ||
| Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans | Q34256239 | ||
| Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors | Q34432988 | ||
| Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease | Q34993666 | ||
| Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis | Q35594898 | ||
| Statins and liver toxicity: a meta-analysis | Q35783702 | ||
| Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review | Q36714163 | ||
| Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) | Q39859200 | ||
| Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation | Q41898952 | ||
| The relationship between microvascular endothelial function and carotid-radial pulse wave velocity in patients with mild hypertension | Q42844881 | ||
| Primary biliary cirrhosis is associated with oxidative stress and endothelial dysfunction but not increased cardiovascular risk. | Q42846873 | ||
| Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients | Q43130915 | ||
| Statins in primary biliary cirrhosis: are they safe? | Q43268799 | ||
| Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment | Q43270979 | ||
| Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? | Q43676662 | ||
| Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function | Q43852832 | ||
| Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers | Q43954071 | ||
| Oxidant stress is a significant feature of primary biliary cirrhosis. | Q44360006 | ||
| Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing | Q44491215 | ||
| Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis | Q46661443 | ||
| Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. | Q46861532 | ||
| Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid | Q55174800 | ||
| P433 | issue | 8 | |
| P921 | main subject | simvastatin | Q670131 |
| primary biliary cholangitis | Q1072420 | ||
| P304 | page(s) | 1166-1174 | |
| P577 | publication date | 2013-05-15 | |
| P1433 | published in | Liver International | Q15765078 |
| P1476 | title | Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis | |
| P478 | volume | 33 |
| Q92931544 | Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial |
| Q26766699 | Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver |
| Q27023122 | Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress |
| Q92577543 | Guideline-conform statin use reduces overall mortality in patients with compensated liver disease |
| Q41982359 | Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis |
| Q38175055 | Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis |
| Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
| Q24186852 | Pharmacological treatments for primary biliary cirrhosis: a network meta-analysis |
| Q26741176 | Pleiotropic effects of statins in the diseases of the liver |
| Q35308878 | Predictors of liver failure in primary biliary cirrhosis |
| Q26781780 | Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective |
| Q57141930 | Primary biliary cirrhosis |
| Q39171942 | Rationale for the use of statins in liver disease. |
| Q55395737 | Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review. |
| Q58097774 | Safety and efficacy of statin therapy |
| Q35232279 | Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel |
| Q38656007 | Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects |
Search more.